^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Testicular Cancer

    Related cancers:
    2d
    Inflammatory and Nested Testicular Sex Cord Tumors: Clinical and Molecular Characterization. (PubMed, Genes (Basel))
    Published cases suggest that IN-TSCT may exhibit aggressive clinical behavior, including metastatic spread in a subset of patients; however, the total number of reported cases remains very limited, and the true metastatic risk and prognostic spectrum have not yet been clearly defined. This review synthesizes the available literature to provide a comprehensive clinicopathologic and molecular overview of this emerging tumor entity.
    Review • Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • TNFRSF8 (TNF Receptor Superfamily Member 8) • EWSR1 (EWS RNA Binding Protein 1) • ATF1 (Activating Transcription Factor 1)
    |
    TMB-L • TNFRSF8 expression
    2d
    TESTIGO: Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer (clinicaltrials.gov)
    P=N/A, N=160, Recruiting, Sahlgrenska University Hospital
    New trial • HEOR
    |
    etoposide IV • bleomycin
    3d
    Intratesticular Serous Borderline Tumor: A Clinicopathologic and Molecular Analysis of Four Tumors With Literature Review. (PubMed, Int J Surg Pathol)
    Intratesticular SBTs are rare Müllerian-type neoplasms that can closely mimic other more aggressive neoplasms. Recognition of their characteristic morphology and immunoprofile, together with emerging molecular insights, is helpful to avoid misdiagnosis and overtreatment.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • WT1 (WT1 Transcription Factor) • CHEK2 (Checkpoint kinase 2) • KRT7 (Keratin-7) • PAX8 (Paired box 8)
    4d
    PROHEAR: ACOU085 for Hearing Loss Prevention in Testicular Cancer Patients Receiving Cisplatin (clinicaltrials.gov)
    P2, N=40, Completed, Acousia Therapeutics GmbH | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin
    5d
    Utility of 18F-FDG PET/CT in the Surveillance of Patients With Neurofibromatosis Type 1. (PubMed, Neurol Genet)
    In this cohort of 79 adult patients with NF1, 18F-FDG PET/CT proved as a valuable complementary imaging modality to conventional imaging by enabling the detection of incidental malignant or potentially malignant tumors. Our results highlight 18F-FDG PET/CT's beneficial impact on disease management by suggesting that the incorporation of 18F-FDG PET/CT into screening protocols could improve early detection of NF1-related cancers in asymptomatic adults, potentially offering early treatment options to improve clinical outcomes.
    Journal
    |
    NF1 (Neurofibromin 1)
    11d
    HFB-200301-01: A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=72, Completed, HiFiBiO Therapeutics | Suspended --> Completed
    Trial completion • First-in-human
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600
    |
    Tevimbra (tislelizumab-jsgr) • emunkitug (HFB200301)
    11d
    SUR-CAN: Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring (clinicaltrials.gov)
    P2, N=88, Recruiting, Centre Oscar Lambret | Trial completion date: Oct 2029 --> Jul 2032
    Trial completion date • Compliance
    12d
    XmAb541-01: Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=282, Recruiting, Xencor, Inc. | N=212 --> 282
    Enrollment change • First-in-human
    |
    CLDN6 (Claudin 6)
    14d
    Evaluating Claudin-6 and isochromosome 12p in the progression from germ cell neoplasia in situ to primary testicular germ cell tumor and post-chemotherapy teratoma: implications for CLDN6-targeted therapies. (PubMed, Ther Adv Med Oncol)
    CLDN6-targeted therapies may not be effective for teratoma. In contrast, i12p was prevalent across all stages of GCT progression, suggesting its potential as a biomarker for identifying viable GCT.
    Journal
    |
    CLDN6 (Claudin 6)
    17d
    Tertiary lymphoid structures in genitourinary cancers: a comprehensive review. (PubMed, Front Oncol)
    Notably, mature TLSs are key for effective anti-tumor immunity, whereas immature TLSs may fail to generate an adequate response. Collectively, these findings highlight TLSs as prognostic biomarkers with prognostic value and therapeutic potential in GU malignancies.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • SERPINB9 (Serpin Family B Member 9)